Article

Hyperbilirubinemia during Atazanavir Treatment in 2,404 Patients in the Italian Atazanavir Expanded Access Program and MASTER Cohorts

School of Medicine, Institute of Infectious and Tropical Diseases, University of Brescia, P.le Spedali Civili, 1, 25123, Brescia, Italy.
Infection (Impact Factor: 2.86). 07/2009; 37(3):244-9. DOI: 10.1007/s15010-008-8010-6
Source: PubMed

ABSTRACT Although the mechanism of atazanavir (ATV)-related hyperbilirubinemia is well identified, its prevalence, risk factors, and association with transaminase flares have rarely been assessed in a large population from the "real life" setting.
Prospectively collected data on 2,404 patients from the Italian MASTER Cohort and the Italian ATV expanded access program database were examined. Uni- and multivariable Cox proportional hazards regression models were conducted to identify risk factors for grade >or= III hyperbilirubinemia during the administration of ATV. The risk of increased levels of serum alanine aminotransferase (ALT) was compared between patients with or without grade >or= III hyperbilirubinemia in a Cox regression analysis stratified by hepatitis C virus (HCV) serostatus.
Grade III and IV hyperbilirubinemia were observed in 1,072 (44.6%) and 174 (7.2%) of the patients, respectively. Higher CD4+ T-cell counts, abnormal bilirubinemia at baseline, and ritonavir co-administration were associated with a higher risk of developing grade >or= III hyperbilirubinemia. In contrast, female gender, clinical class C, and non-nucleoside reverse transcriptase co-administration appeared to be protective. Higher bilirubinemia at baseline and the use of ritonavir were associated with a higher risk of grade IV hyperbilirubinemia. The occurrence of grade >or= III hyperbilirubinemia was not associated with severe hepatotoxicity (hazard ratio 1.00, 95% confidence interval 0.64-1.57; p = 0.997).
Hyperbilirubinemia is a common side effect of an ATV pharmacotherapeutic regimen. However, grade IV increase in bilirubin was rarely found. In most cases, ATV hyperbilirubinemia appeared to be an innocent phenomenon as far as the risk of a subsequent increase in liver enzyme level is concerned.

Download full-text

Full-text

Available from: Giuliano Rizzardini, Aug 17, 2015
0 Followers
 · 
141 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The sensitivity of the digital equipments to the voltage variations of short duration has raised studies and evaluations that seek a better understanding of the electric and magnetic compatibility between supply and load. To guarantee a normal operation of the personal computers, it is a common practice among individuals and companies the installation of voltage regulators just before the computers. The switch power supplies in the personal computers are sensitive to voltage variations of short duration, and the voltage regulators are adopted as additional equipment for protection of the computers against the electric disturbances. However, the voltage regulators and the switch power supplies present a similar tolerance level to voltage variations of short duration. This paper presents the results of computer simulation and experimental tests of the voltage response for switch power supplies and voltage regulators when submitted to voltage sags and interruptions of short duration. The tests were accomplished based on the international standard of IEC 61000-4-11 that defines methods of immunity test and preferential range of values for electric and/or electronic equipments connected to the low voltage of a distribution network. The behaviour of the tested equipments offers subsidies to corroborate the practical use of personal computers associated to the voltage regulators.
    IECON 02 [Industrial Electronics Society, IEEE 2002 28th Annual Conference of the]; 12/2002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Using sandwich-cultured hepatocytes from rat, dog, pig, and human, we investigated the species-specificity of interaction of HIV protease inhibitors (PI) with in vitro hepatic accumulation of the bile salt analogue cholyl-glycylamido-fluorescein (CGamF). Extracellular sodium depletion or coincubation with the OATP/Oatp inhibitors rifampicin and digoxin revealed that about 35% of active CGamF accumulation was mediated by Ntcp/NTCP in rat and human hepatocytes, while the contribution of this sodium-dependent transporter reached 50-60% in dog and pig hepatocytes. One or more sodium-independent transporters, likely belonging to the Oatp/OATP family, constitute a major transport mechanism for CGamF accumulation. Various HIV PI (0.5, 5, 25 microM) exhibited pronounced species differences in their interaction with active CGamF accumulation (1 microM), although some similarity was observed between the dog and human interaction profiles when HIV PI were tested at 0.5 microM. Atazanavir, indinavir, and darunavir were the most potent inhibitors of CGamF accumulation in human hepatocytes. Potent inhibition of CGamF accumulation by ritonavir in rat hepatocytes contrasted with a weak effect in human hepatocytes. Thorough characterization of in vitro disposition of probe substrates in preclinical species compared to human hepatocytes will ultimately support a better insight in species-specific mechanisms underlying drug interactions and drug-mediated toxicity.
    Journal of Pharmaceutical Sciences 01/2009; 99(6):2886-98. DOI:10.1002/jps.22018 · 3.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: HIV-infected adolescents represent a unique, yet diverse, population requiring specialized medical and psychosocial HIV care. Perinatally infected and behaviorally infected adolescents often have differing therapeutic needs, but may share common difficulties, including medication nonadherence, high-risk sexual behavior, psychosocial stressors, and concomitant psychiatric disorders. Addressing these needs within a culturally sensitive framework and in the context of a population-specific approach to treatment is paramount to optimizing care. Harm reduction for this group to maximize their health and limit HIV transmission to others is also critical with respect to the rising incidence of newly diagnosed HIV-positive adolescents. Implementing a formal, multidisciplinary program that involves individual youths and their families for improved transition to adult HIV care will afford such adolescents a better chance for a healthy adulthood.
    Current Infectious Disease Reports 01/2010; 12(1):63-70. DOI:10.1007/s11908-009-0077-4
Show more

Similar Publications